We met with Dr. Alok Khorana in Berlin during the ISTH 2017 Congress. He could not hide his enthusiasm about the discoveries of the Vienna group and about two trials using his Khorana risk score: the Cassini study, co-chaired with Prof. Lyman, and the AVERT study, also led by Marc Carrier and Phil Wells. Both of them include patients with a > 2 risk score, which he believes they will constitute a big step forward in knowledge for prevention of CAT.
As per treatment of CAT goes, he looks forward to hearing the results of HOKUSAI (edoxaban vs warfarin) and SELECT-D (rivaroxaban vs LWMH) trial.
Hear his own words!
None of the information published on the ICTHC magazine website, in particular, information related to the choice and use of drugs, replaces the advice of a doctor.
Accept to continue
By registering to the newsletter, the User’s email address will be added to the contact list of ICTHIC Magazine, in order to receive email messages concerning the content published in ICTHIC Magazine and related promotional content/activities. Your email address may also be added to this list as a result of signing up to this Website. Personal Data collected: email address, first name, last name, profession.
ICTHIC CONFERENCE Newsletter By registering to the newsletter, the User’s email address will be added to the contact list of ICTHIC, in order to receive newsletters concerning the conference, such as Save the date, information about the meeting venue, the publication of the program, registration fees and deadline, abstract submission deadline and oral communication/poster instructions, hotel booking availability and deadline, social program for accompanying persons, the publication of speakers slides, photo/videogallery of the last edition and information about future editions of the conference. Your email address may also be added to this list as a result of signing up to this Website.